Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. [electronic resource]
Producer: 20050829Description: 3025-31 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Antigens, Nuclear -- genetics
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cell Cycle Proteins -- genetics
- Cisplatin -- administration & dosage
- DNA-Binding Proteins -- genetics
- Dihydrouracil Dehydrogenase (NADP) -- genetics
- Endonucleases -- genetics
- Female
- Fluorouracil -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Ku Autoantigen
- Male
- Middle Aged
- Neoadjuvant Therapy
- Nuclear Proteins -- genetics
- Predictive Value of Tests
- Prognosis
- RNA, Messenger -- genetics
- Reverse Transcriptase Polymerase Chain Reaction -- methods
- Stomach Neoplasms -- drug therapy
- Survival Analysis
- Thymidine Phosphorylase -- genetics
- Thymidylate Synthase -- genetics
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.